Tamorie Smith, MD
Nephrology · Columbus, GANPI 1215140496
Payments from drug & device makers
Across 417 payments — averaging $4499.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$1.5M
- Medtronic$141K
- Vertex$106K
- Akebia Therapeutics Inc$56K
- Takeda Pharmaceuticals U.S.A., Inc.$32K
- AstraZeneca$704
- plus $3K from 20 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 149 | $1,536,998 |
| Medtronic | 6 | $141,453 |
| Vertex | 4 | $106,445 |
| Akebia Therapeutics Inc | 103 | $55,607 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $32,446 |
| AstraZeneca(2 entities) | 32 | $704 |
| Mallinckrodt Hospital Products Inc. | 10 | $451 |
| Otsuka America Pharmaceutical, Inc. | 11 | $277 |
| Baxter Healthcare | 6 | $252 |
| OPKO Pharmaceuticals, LLC | 11 | $189 |
| Novo Nordisk | 12 | $175 |
| Vifor Pharma, Inc. | 4 | $173 |
| Bayer | 8 | $172 |
| Amgen(2 entities) | 7 | $171 |
| Travere Therapeutics, Inc. | 19 | $166 |
| GSK | 5 | $146 |
| Novartis | 5 | $109 |
| Calliditas Therapeutics US Inc. | 5 | $102 |
| Ardelyx, Inc. | 4 | $94 |
| Cormedix Inc. | 2 | $64 |
| Fresenius USA Marketing, Inc. | 3 | $55 |
| Alnylam Pharmaceuticals Inc. | 3 | $52 |
| Daiichi Sankyo Inc. | 2 | $33 |
| Mallinckrodt Enterprises LLC | 1 | $23 |
| Apellis Pharmaceuticals, Inc. | 1 | $20 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $15 |
How this compares
$1,876,390 in reported general payments places this provider in the 95th percentile of 388 nephrology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other nephrology in Columbus
- Rajeev ChauhanColumbus$1.1M
- Rajendran AlappanColumbus$346K
- Arachelvi DhandayuthapaniColumbus$110K
- Fahd SyedColumbus$48K
- James TumlinLawrenceville$19.8M
- Chinedu NwekeAcworth$3.9M
- Vinayak RamanathLagrange$3.1M
- Harold HubertAugusta$2.8M
- Barton BrezinaAugusta$1.5M
- Frederic Rahbari OskouiAtlanta$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.